Claudins and Ki-67: Potential Markers to Differentiate Low- and High-Grade Transitional Cell Carcinomas of the Urinary Bladder

Journal of Histochemistry and Cytochemistry

Volumn 59, Issue 11, 2011, Pages 1022-1030

  Törzsök, Péter ^a   Riesz, Péter ^b   Kenessey, István ^a   Székely, Eszter ^a   Somorácz, Áron ^a   Nyirády, Péter ^b   Romics, Imre ^b   Schaff, Zsuzsa ^a   Lotz, Gábor ^a   Kiss, András ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

claudin; tight junction; transitional cell carcinoma; urinary bladder cancer

Indexed keywords

CLAUDIN; CLAUDIN 1; CLAUDIN 10; CLAUDIN 2; CLAUDIN 3; CLAUDIN 4; CLAUDIN 5; CLAUDIN 7; KI 67 ANTIGEN; MESSENGER RNA; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; UROTHELIUM; BLADDER TUMOR; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

CARCINOMA, TRANSITIONAL CELL; CLAUDINS; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOPLASM GRADING; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84555191362     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155411424606     Document Type: Article

References (39)

1. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle- invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54:303-314.
2. Balda MS, Matter K. Tight junctions and the regulation of gene expression. Biochim Biophys Acta. 2009;1788:761-767.
3. Bello IO, Vilen ST, Niinimaa A, Kantola S, Soini Y, Salo T. Expression of claudins 1, 4, 5, and 7 and occludin, and relationship with prognosis in squamous cell carcinoma of the tongue. Hum Pathol. 2008;39:1212-1220.
4. Boireau S, Buchert M, Samuel MS, Pannequin J, Ryan JL, Choquet A, Chapuis H, Rebillard X, Avances C, Ernst M, et al. DNA-methylation-dependent alterations of claudin-4 expression in human bladder carcinoma. Carcinogenesis. 2007;28:246-258.
5. Bryan RT, Zeegers MP, James ND, Wallace DM, Cheng KK. Biomarkers in bladder cancer. BJU Int. 2010;105:608-613.
6. Chao YC, Pan SH, Yang SC, Yu SL, Che TF, Lin CW, Tsai MS, Chang GC, Wu CH, Wu YY, et al. Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med. 2009;179:123-133.
7. Chen YB, Tu JJ, Kao J, Zhou XK, Chen YT. Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma. Arch Pathol Lab Med. 2008;132:224-231.
8. Damjanov I, Mikuz G. Cancer Grading Manual. Damjanov IFan F, ed. New York: Springer; 2007:55-63.
9. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331:1259-1264.
10. Gaisa N, Braunschweig T, Reimer N, Bornemann J, Eltze E, Siegert S, Toma M, Villa L, Hartmann A, Knuechel R. Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer. Virchows Arch. 2010;458:301-312.
11. Heney NM. Natural history of superficial bladder cancer: prognostic features and long-term disease course. Urol Clin North Am. 1992;19:429-433.
12. Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin. 2010;60:244-272.
13. Jones TD, Wang M, Eble JN, MacLennan GT, Lopez-Beltran A, Zhang S, Cocco A, Cheng L. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res. 2005;11:6512-6519.
14. Kakiashvili DM, van Rhijn BW, Trottier G, Jewett MA, Fleshner NE, Finelli A, Azuero J, Bangma CH, Vajpeyi R, Alkhateeb S, et al. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guerin treatment. BJU Int. 2011;107:540-546.
15. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239-249.
16. Kleinberg L, Holth A, Trope CG, Reich R, Davidson B. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum Pathol. 2008;39:747-757.
17. Lal-Nag M, Morin PJ. The claudins. Genome Biol. 2009;10:235.231-235.237.
18. Lanigan F, McKiernan E, Brennan DJ, Hegarty S, Millikan RC, McBryan J, Jirstrom K, Landberg G, Martin F, Duffy MJ, et al. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer. 2009;124:2088-2097.
19. Lechpammer M, Resnick MB, Sabo E, Yakirevich E, Greaves WO, Sciandra KT, Tavares R, Noble LC, DeLellis RA, Wang LJ. The diagnostic and prognostic utility of claudin expression in renal cell neoplasms. Mod Pathol. 2008;21:1320-1329.
20. Lioni M, Brafford P, Andl C, Rustgi A, El Deiry W, Herlyn M, Smalley KS. Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. Am J Pathol. 2007;170:709-721.
21. Lodi C, Szabo E, Holczbauer A, Batmunkh E, Szijarto A, Kupcsulik P, Kovalszky I, Paku S, Illyes G, Kiss A, et al. Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas. Mod Pathol. 2006;19:460-469.
22. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res. 2006;12:7369-7373.
23. Martin TA, Jiang WG. Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta. 2009;1788:872-891.
24. May M, Brookman-Amissah S, Roigas J, Hartmann A, Storkel S, Kristiansen G, Gilfrich C, Borchardt R, Hoschke B, Kaufmann O, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol. 2010;57:850-858.
25. Miyamoto H, Brimo F, Schultz L, Ye H, Miller JS, Fajardo DA, Lee TK, Epstein JI, Netto GJ. Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. Arch Pathol Lab Med. 2010;134:1160-1163.
26. Miyamoto K, Kusumi T, Sato F, Kawasaki H, hibata S, Ohashi M, Hakamada K, Sasaki M, Kijima H. Decreased expression of claudin-1 is correlated with recurrence status in esophageal squamous cell carcinoma. Biomed Res. 2008;29:71-76.
27. Morita K, Furuse M, Fujimoto K, Tsukita S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci U S A. 1999;96:511-516.
28. Nakanishi K, Ogata S, Hiroi S, Tominaga S, Aida S, Kawai T. Expression of occludin and claudins 1, 3, 4, and 7 in urothelial carcinoma of the upper urinary tract. Am J Clin Pathol. 2008;130:43-49.
29. Nichols LS, Ashfaq R, Iacobuzio-Donahue CA. Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol. 2004;121:226-230.
30. Paschoud S, Bongiovanni M, Pache J-C, Citi S. Claudin-1 and claudin-5 expression patterns differentiate lung squamous cell carcinomas from adenocarcinomas. Mod Pathol. 2007;20:947-954.
31. Saeki R, Kondoh M, Kakutani H, Matsuhisa K, Takahashi A, Suzuki H, Kakamu Y, Watari A, Yagi K. A claudin-targeting molecule as an inhibitor of tumor metastasis. J Pharmacol Exp Ther. 2010;334:576-582.
32. Santos L, Amaro T, Costa C, Pereira S, Bento MJ, Lopes P, Oliveira J, Criado B, Lopes C. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer. 2003;105:267-272.
33. Sobel G, Nemeth J, Kiss A, Lotz G, Szabo I, Udvarhelyi N, Schaff Z,Paska C. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma. Gynecol Oncol. 2006;103:591-598.
34. Steed E, Balda MS, Matter K. Dynamics and functions of tight junctions. Trends Cell Biol. 2010;20:142-149.
35. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA. The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. Eur Urol. 2009;55:815-825.
36. Szabo I, Kiss A, Schaff Z, Sobel G. Claudins as diagnostic and prognostic markers in gynecological cancer. Histol Histopathol. 2009;24:1607-1615.
37. Szasz AM, Nyirady P, Majoros A, Szendroi A, Szucs M, Szekely E, Tokes AM, Romics I, Kulka J. Beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression. BJU Int. 2010;105:716-722.
38. Szekely E, Torzsok P, Riesz P, Korompay A, Fintha A, Szekely T, Lotz G, Nyirady P, Romics I, Timar J, Schaff Z, Kiss A. Expression of claudins and their prognostic significance in noninvasive urothelial neoplasms of the human urinary bladder. J Histochem Cytochem. 2011;59:932-941.
39. Varley CL, Garthwaite MA, Cross W, Hinley J, Trejdosiewicz LK, Southgate J. PPARgamma-regulated tight junction development during human urothelial cytodifferentiation. J Cell Physiol. 2006;208:407-417.